Back to News
Market Impact: 0.2
Cantor Fitzgerald Initiates Coverage of Ovid Therapeutics with Overweight Rating
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
On October 9, 2026, Cantor Fitzgerald initiated coverage of Ovid Therapeutics with an Overweight recommendation. The article provides no price target, rationale, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
OVID0.45
More News
- Wall Street sees buying opportunity in banks as shares tank ahead of earnings
- This exchange stock is a buy on renewed options deal, Morgan Stanley says
- Cramer: Investors selling Apple on latest iPhone 18 report are 'stupid as plywood'
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings